採納股份(301122.SZ):子公司取得醫療器械註冊證 為一次性使用胰島素筆配套用針
格隆匯4月18日丨 採納股份(301122.SZ)公佈,公司全資子公司江蘇採納醫療科技有限公司(“採納醫療”)於近日收到國家藥品監督管理局頒發的《中華人民共和國醫療器械註冊證》,產品名稱為一次性使用胰島素筆配套用針。
採納醫療此次獲得醫療器械註冊證的一次性使用胰島素筆配套用針產品由針座蓋貼、外針帽、針座、內針帽和針管組成。產品經環氧乙烷滅菌,一次性使用。此次醫療器械註冊證的取得,進一步完善了公司在醫用業務板塊的產品結構,有助於公司推進相關產品的國內銷售,對公司未來發展將產生積極影響。但該產品的實際銷售情況取決於未來市場的推廣效果,公司目前尚無法預測其對公司未來業績的具體影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.